Streetwise Biotech / Pharmaceuticals Articles



Is This Pharma Set To Break Out After COPD Drug Approval?
Source: Streetwise Reports  (3/15/24)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024. More >


Chris Temple

This Biotech Is a Potential Disruptor, Expert Says
Source: Chris Temple  (3/12/24)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy. More >


NY Biotech Has Potentially Game Changing Anxiety Therapy
Source: Dr. Jonathan Aschoff  (3/7/24)
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note. More >


Alt-Pharma VC adds 7% Stake in Testing Strip Firm
Source: Streetwise Reports  (2/15/24)
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio. More >


Ron Struthers

Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says
Source: Ron Struthers  (2/12/24)
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly. More >


Drug Reformer Subsidiary Inspected for Dealer License
Source: Streetwise Reports  (2/2/24)
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances. More >


Leadership Cuts Won't Slow This Biotech
Source: Robert Burns  (1/26/24)
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report. More >


Pharma Co. Primed for Future Business
Source: Dr. Andre Uddin  (1/25/24)
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development. More >


Healthcare Co. Exceeds Expectations in Performance
Source: Dr. Yi Chen  (1/24/24)
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note. More >


Money Manager: The Year of Small Caps?
Source: Streetwise Reports  (1/16/24)
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps. More >


Big Pharma's Looming Patents May Benefit One Biotech
Source: Streetwise Reports  (1/10/24)
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024. More >


Biotech Co.'s Sales Could Grow To US$310 Million in 2028
Source: Edward White  (1/10/24)
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report. More >


2024: Chen Leads With Biotech After Picking 2023's Top Stock
Source: Streetwise Reports  (1/5/24)
Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year. More >


Ron Struthers

Market Correction and One Cash Rich Biotech
Source: Ron Struthers  (1/3/24)
In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value. More >


Boston Biotech Could Have Blockbuster Sales
Source: Robert Burns  (1/3/24)
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report. More >


Pharma Co. Gets First US Patent for Repurposed Drug
Source: Streetwise Reports  (1/2/24)
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast. More >


California-Based Pharma Co.'s Progress Offers Upside
Source: Dr. Swayampakula Ramakanth  (1/2/24)
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company. More >


Co.'s Breast Cancer Therapy Shows Encouraging Activity
Source: Emily Bodnar  (12/28/23)
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report. More >


Biotech Secures Additional Funding, Extending Cash Runway
Source: Ed Arce  (12/27/23)
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co. More >


Biotech Bolsters ADC Pipeline Through Atreca Asset Buy
Source: Dr. David Nierengarten  (12/26/23)
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush. More >


US Biotech's Anti-Fungal Wins European Approvals
Source: Ed Arce  (12/22/23)
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co. More >


Biotech Co. Reports Encouraging ALS Data but FDA Wants More
Source: Dr. Jonathan Aschoff  (12/21/23)
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM. More >


Pharma Co. May Have Accelerated FDA Approval in 2024
Source: Edward White  (12/20/23)
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co. More >


Bioscience Co. Expands Collaboration
Source: Dr. Jonathan Aschoff  (12/19/23)
This bioscience company's price target implies 680% upside, according to a Roth MKM report. More >


Ron Struthers

Promising Biotech Selling Way Under Cash Value
Source: Ron Struthers  (12/18/23)
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater. More >


Showing Results: 1 to 25 of 1871 Next

Notable Quotes

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"REVV completed the proposed acquisition of WindRiver."
– Shawn Severson, Water Tower Research
"The hanging wall area seems likely to double WEX's Au resource."
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"TAO should be fracking this month."
– Chen Lin, What Is Chen Buying? What Is Chen Selling?